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Abstract 
It is determined that 30% of patients with depression are resistant to antidepressant medication. The increased 
concentration of inflammation factors, such as C-reactive protein, and pro-inflammatory cytokines, have been 
detected in serum in these patients. It is necessary to establish new therapeutic possibilities and protocols that 
are created to overcome the difficulties caused by increased concentration of inflammatory biomarkers in 
depressive patients. The Selective Serotonin Reuptake Inhibitors (SSRIs) are considered to be the most powerful 
antidepressants, increasing the level of serotonin in endogenous depression, as well as in that caused by 
immunological mechanisms. It is believed that agents that influence cytokines, immunological signal pathways 
and cytokine syntheses, like the inhibitors of cyclooxygenase enzyme and other non-steroidal anti-inflammatory 
drugs (NSAIDs), are very important in the potential treatment of residual symptoms of depression. Treatment with 
cytokine antagonists is one of the potential adjuvant therapies, along with antidepressants. Signal pathways 
blockers, such as the inhibitors of cyclooxygenase and other NSAIDs, are in the phase of research, in terms of 
their antidepressant effects. Also, it has been shown that the inhibition of indolamin-2,3 deoxygenase (IDO) and 
kynurenine (KYN) signal pathways in the synthesis of neurotransmitters, by application of IDO antagonists, are 
leading to suppression of pro-inflammatory cytokine effects. Antidepressants may have anti-inflammatory effects, 
depending on dose and type, and they achieve this effect through the decrease of pro-inflammatory cytokine 
production and increase of anti-inflammatory cytokines. Also, antidepressants modulate the humoral and cellular 
immune system. This work aims to summarise certain neurobiological and neuroimmunological specificities that 
have been observed in patients with depression, antidepressants and immunomodulation agents. The 
understanding of complex and heterogenic pathophysiology of depression through the prism of the altered 
immune system, is of major importance, in terms of better optimisation of pharmacotherapy, and options for a 
personalised approach in depressive disorder treatment. 
 
 
 
 
Introduction 
 
In the last 20 years, the great expansion of 
biological psychiatry, that is neurosciences, has been 
observed. They aim to decode still insufficiently 
explored psychiatric diseases, like depression, which 
is a leading cause of morbidity worldwide, because of 
its high prevalence. This situation is certainly the 
result of the development of molecular, genetic and 
neuroimaging techniques that enable the changing of 
current viewing of causes, course and treatment of 
psychiatric diseases.  
The understanding of the comprehensive and 
heterogenic etiopathogenesis of depression, that 
more and more implements the role of the altered 
immune system is of major importance for better 
determination of pharmacotherapy. Because 
numerous studies confirm the contribution of the 
activated immune system and its factors in the 
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occurrence of depressive disorder, it is necessary to 
modify already existing pharmacotherapy, as well as 
to investigate new options, in terms of 
immunomodulating agents. The researches done so 
far have shown that innate immunity is mostly 
involved in the pathophysiology of depressive 
disorder, that is the activity of pro-inflammatory 
cytokines. It is believed that anti-inflammatory agents 
that establish the homeostasis of the immune system 
may have a role in the reduction of depressive 
symptoms. The levels of biomarkers such as C-
reactive protein, tumour necrosis factor (TNF) and 
interleukin (IL)-1, as well as IL-6, are often increased 
in depressive patients, especially in those that are 
resistant to antidepressant treatment. They account 
for 30% of all patients with depression [1], [2]. This is 
often provoked by distress because distress activates 
the immune system, especially the one in earlier 
stages of life, and more likely if there is a genetic 
predisposition involved. Already mentioned pro-
inflammatory cytokines activate pro-inflammatory 
prostaglandin E2 (PGE2), which has a leading role in 
inflammation mediation [1].  
Pro-inflammatory cytokines created and 
released in the brain interact with neurotransmitters, 
by activating tryptophan and serotonin-degradation 
enzymes indolamin-2, 3 dioxygenases (IDO) and by 
increasing the activity of serotonin transporters. This 
further leads to the decrease of serotonin available in 
the synaptic crack. Pro-inflammatory cytokines may 
be the future in the establishment of more successful 
antidepressant therapy, because they may be the 
target of anti-inflammatory therapy and modifiers of 
cytokine signals, in terms of defined biomarkers [3]. 
Tryptophan/kynurenine system (KYN) that is 
dominantly described in studies about 
immunopathogenesis of depression provides the 
subtlest relation between depression, distress and 
immunity [1], [4].  
Metabolic product of KYN system are 
neurotoxic kynulonic acid which damages certain 
brain regions of depressive patients, on the one hand, 
and leads to the decrease of neurotransmitter level, 
on the other [5]. Finally, it is considered that patients 
with activated immune system are prone to weaker 
reaction to standard antidepressant therapy, and there 
is a hypothesis that this kind of patients would better 
react on therapy with antidepressants, along with the 
augmentation with immunosuppressive agents, that 
are expected to stable inflammation factors in non-
responders to treatment [6]. On the other hand, it has 
been shown that antidepressants may inhibit the 
production and function of peripheral brain cytokines. 
They may decrease the level of pro-inflammatory 
cytokines, with the increase of anti-inflammatory 
cytokine levels which also contribute to depressive 
symptoms reduction [7]. 
 
 
Role of anti-inflammatory agents as 
antidepressants 
 
New possibilities in depression treatment are 
the target pathways by which the immune system 
influences the brain, such as cytokines or growth 
factors, as well as the activation of relevant brain 
immune cells, like microglial cells. Monocytes and 
microglial cells may be returned on a basic level of 
functioning by application of immunosuppressive 
medications, including non- steroidal anti-
inflammatory agents, like Minocycline and N-
acetylcysteine. Unfortunately, these agents are not 
investigated in psychiatric disorders quite enough, 
along with their potential for further and new 
immunosuppressive interventions. N-acetylcysteine, 
Minocycline and other non-steroidal anti-inflammatory 
agents are aggressively tested on animal models, 
aiming to get an estimation of their impact on 
behavioural abnormalities [6]. Immunosuppressive 
agents that are currently in the focus of interest are 
cytokine antagonists, most of all TNF and IL-6, non-
steroidal anti-inflammatory agents, as well as certain 
immunomodulation agents. Also, it is determined that 
the inhibition of IDO and KYN pathways leads to the 
suppression of cytokine effects on the glutaminergic 
system, thus on behaviour disturbances in depression 
[2], [8]. The agents affecting hypothalamic-pituitary-
adrenal (HPA) axis, glucocorticoid receptors (GRs), 
and post-receptor signal pathways are considered as 
possible therapeutic possibilities, with the potential to 
correct the dysregulation of this endocrine axis in 
depressive disorder. The medications classified as 
anti-glucocorticoids (GR antagonists, GR agonists, 
dehydroepiandrosterone – DEHA, the inhibitors of 
steroid synthesis) have potential abilities to stabilise 
the inflammation associated with the activity of 
glucocorticoids that may have the role in brain 
damage in depressive patients. The studies 
supporting this concept of development of the 
potential antidepressant therapy are still in the 
beginning phase [6]. The agglomeration of evidence 
on immunological distortions plays the crucial role in 
further discovering of still insufficiently defined 
aetiology of depressive disorder, along with 
distinguishing single groups of patients who share 
immunologic, genetic and brain alterations, and also 
an individual response to antidepressant treatment [9]. 
The side effects of anti-inflammatory medications 
must be beard in mind, primarily severe infections due 
to induced immunosuppression [10]. 
 
 
Cytokine inhibitors 
 
If it is supposed that cytokines are involved in 
depression development, then cytokine-like 
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antidepressants (e.g. receptors antagonists which can 
regulate pro-inflammatory cytokines and anti-cytokine 
antibodies) may improve depressive symptoms. 
Cytokine antagonists that are wide-spectrum anti-
inflammatory cytokines, such as IL-4 and IL-10 may 
be more effective than cytokine antagonists which 
inhibit specific cytokines in depressive treatment. TNF 
antagonists, like Adalimumab, Etanercept and 
Infliximab have been used as therapeutic agents in 
the treatment of autoimmune diseases, such as 
rheumatoid arthritis, and are currently used in clinical 
trials in the treatment of depressive episodes of 
bipolar disorder [7]. Already mentioned Adalimumab, 
Infliximab, as well as Golimumab, are monoclonal 
antibodies, unlike Etanercept, which is circulating TNF 
receptor fusion protein. These agents have shown 
their potential antidepressant effects, first on animal 
models, and in patients with chronic inflammatory 
diseases, like Chron’s disease, ankylosing spondylitis, 
along with accompanying depressive symptoms [11]. 
It is determined that anti-TNF therapy, like Etanercept, 
which is administered in patients who have psoriasis, 
has a potential adjuvant effect in combination with 
certain antidepressants [6], [10]. It is supposed that 
the antidepressant effect of Etanercept is a 
consequence of potentiation of serotoninergic and 
noradrenergic neurotransmission, as well as of 
normalisation of stress hormone secretion.  
Chronic therapy with Infliximab prevents the 
decreasing of brain neurotrophic factor (BDNF) in the 
hippocampus. It has been shown that chimeric 
monoclonal antibody Infliximab has a potential 
antidepressant effect in patients suffering from 
depression and resistant to treatment, but only in 
those with increased values of inflammatory factors, 
like CRP and TNF, in the way of preventing the 
binding of TNF to its surface cell receptors [1], [10]. 
Anti- TNF therapy affect serotonin transporters, so it 
may influence the efficacy of Fluoxetine, as it is 
described in certain researches. It is unclear if anti-
TNF therapy has the effects of noradrenergic 
transporters. Also, it influences the increased 
production of BDNF, as well as the expression of the 
α-amino-3-hydroxy-5-methyl-4-isoxazole acid receptor 
(AMPAR), which is the effect of Fluoxetine itself. 
Changes in glutamate transmission are shown to be 
significant in response to antidepressant treatment 
[11]. The researches did so far propose the 
hypothesis that TNF represents the regulating factor 
of the apoptotic cascade that can be associated with 
neural and glial loss in bipolar disorder [7]. In a 
depressive episode of bipolar disorder, TNF levels are 
considered as trait markers of this disorder, and TNF 
modulation could be the target of antidepressant 
therapy [3]. In some studies, the link between anti-
inflammatory cytokines and therapy resistance has 
been found [11]. It has been shown that in a group of 
therapy-resistant depressive patients those with 
higher pro-inflammatory cytokine levels better react to 
the cytokine antagonists, compared to placebo. This 
further contributes to the significance of better 
distinction of biological markers which condition the 
individual response to therapy and personalised 
treatment. Also, it should be emphasised that the TNF 
antagonism concept shouldn’t be generalised to all 
therapy-resistant patients [12].  
Due to the heterogeneity of depressive 
aetiology and its complex nature, TNF level is 
increased in certain patients, and decreased in others, 
while it remains unchanged in some of them, even 
after pharmacological treatment [11]. Targeting of IL-6 
pro-inflammatory cytokine with human monoclonal 
antibody Sirucumab may be the potential therapeutic 
approach in depressive patients. Sirucumab is the 
safe and tolerable agent, capable of modifying the 
immune response in a healthy population, as well as 
in patients with inflammatory diseases, such as 
rheumatoid arthritis. This monoclonal antibody may 
represent the prototype of an agent which proves that 
targeting and modifying pro-inflammatory cytokines, 
like IL-6, can considerably affect the pathogenesis 
and therapeutic outcome of mental disorders, 
primarily depressive disorder [13]. 
 
 
Non-steroidal anti-inflammatory drugs 
 
Non-steroidal anti-inflammatory drugs, as it is 
already mentioned, maybe potentially used as an 
adjuvant option in depression treatment, together with 
antidepressants. First of all, it is meant to the 
mechanism of cyclooxygenase-2 (COX-2) and 
cyclooxygenase-1 (COX-1) blocking, as well as to the 
reduction of oxidative stress, preventing of pro-
inflammatory cytokines increasing, and thus 
increasing of serotonin and other brain 
neurotransmitters. Findings from animal and human 
trials have shown certain contradictories, meaning 
that certain studies have found the adjuvant effect of 
acetylsalicylate acid (ASA) and COX-2 selective 
inhibitor Celecoxib, mostly in combination with SSRIs 
[14]. In animal (rats) model, Rofecoxib – COX-2 
inhibitor increases the level of serotonin in the frontal 
and tempo-parietal cortex, which may have an 
antidepressant effect. In a randomized, double-blind 
trial with antidepressants Reboxetine and Celekoxib, it 
has been shown that Celecoxib has a positive 
antidepressant effect, and similar results have been 
obtained from the studies investigating the 
combination of Celekoxib and Sertraline, as well as 
Celekoxib and Fluoxetine [1], [15]. Namely, recent 
studies showed that Celekoxib, as adjuvant agent 
together with Sertraline, more significantly improved 
mood disturbances in depressive patients. Compared 
to the nanotherapeutic approach with antidepressant, 
this is considered to be the consequence of IL-6 pro-
inflammatory cytokine decreasing [10]. Certain animal 
models showed that the combination of 
antidepressant Bupropion and Celekoxib might be 
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potentially beneficial for the strategy of depressive 
treatment in patients with some chronic disease. It has 
been demonstrated that Clekoxib decreases IL-1 pro-
inflammatory cytokine level, without any effect on 
BDNF decreasing [16].  
One study on rat model investigated the 
influence of 3 different antidepressants (Citalopram, 
Sertraline and Paroxetine) and 2 NSAIDs (Ibuprophen 
and Indometacine) on BDNF and nerve trophic factor 
(NGF) releasing, that was dose-dependent, and also 
depended on drug combination and probably on 
incubation period [17]. There are certain investigations 
which support the hypothesis that Aspirin that is ASA 
may be potential antidepressant therapy, both 
individually and as adjuvant. Decreasing of 
inflammatory mediators during stressful procedures, 
or in any potential physiological or biochemical 
mechanism, may represent the possible 
antidepressant effect of Aspirin [18]. Some other 
investigations have shown that NSAIDs in general, as 
well as Paracetamol, inhibit the antidepressant effect 
of Citalopram (both in animal and human trials), unlike 
ASA and COX-2 inhibitors. This discrepancy is a 
result of different effects of NSAIDs, COX-2 inhibitors, 
and salicylates both on antidepressant effect. Also, 
increased risk of gastrointestinal bleeding and certain 
cardiovascular diseases should be considered during 
the chronic use of these medications, especially 
because these issues haven’t been considered in 
earlier studies investigating the potential adjuvant 
effect of these drugs in depression treatment [19]. 
Current investigations neither support nor discourage 
the use of NSAIDs and Paracetamol together with 
antidepressant therapy, because conclusion about 
their favourable or unfavourable effect cannot be 
brought. 
Further detailed investigations are necessary 
to make a distinction which NSAIDs is the safest, and 
the most potent at the same time, in terms of adjuvant 
therapy of depression [15]. 
 
 
The other anti-inflammatory drugs and 
potential antidepressant agents 
 
It has been shown that the expression of Toll-
like receptors (TLRs) is associated with therapeutic 
outcome in depressive patients that indicates the 
relationship between inflammation, depression and 
therapy. Future studies on animal models will show 
the possible antidepressant effect of TLR antagonists 
[20], [21)]. Antiglucocorticoid agents, including 
Ketoconasole and Metyrapone, are tested to 
antidepressant effects, but significant achievements 
have not been observed due to side effects and 
insufficiently known clinical potential of Metyrapone. 
Dexamethasone and Hydrocortisone may also be 
shortly useful for certain depressive symptoms. 
Glutamate antagonists targeting with Ketamine that is 
N-methyl-d-aspartate receptor (NMDA) may be 
possibly efficient for depression therapy. Omega-3 
polyunsaturated fatty acids affect the metabolic and 
inflammatory activity and show certain benefits in 
depressive symptoms reduction. It has been 
demonstrated that the antidepressant effect may be 
mediated by statins through certain neurobiological 
pathways [22]. Statins are agents primarily used to 
decrease lipid level in peripheral blood, but also show 
anti-inflammatory effects. In the context of the 
inflammatory hypothesis of depression, certain studies 
have found that depressive patients who had been 
using statins, along with SSRIs, had had more stable 
remission with the rarer occurrence of relapses, 
compared to those who had been on monotherapy 
with antidepressant [1]. It is interesting to say that a 
high level of homocysteine in serum is also associated 
with the risk of cardiovascular diseases and 
depression. B vitamin consummation (B6, B9 and 
B12) decreases homocysteine level by 15%, and it is 
also meant that antithrombotic therapy, namely 
Aspirin, decreases homocysteine level. That’s why in 
older people who use Aspirin regularly in their therapy 
and who have higher homocysteine level, the 
occurrence of depression is uncommon. However, 
further randomised trials are necessary to confirm this 
Aspirin feature in people with an increased level of 
homocysteine [23]. 
Animal model of stress-induced depression 
that was presented with behavioural and biochemical 
alteration of the already mentioned KYN pathway has 
shown the antidepressant effect of IDO inhibitor (1-
methyl-D-tryptophane) that is very similar to 
antidepressant Fluoxetine. It has been observed that 
1-methyl-D-tryptophane and Fluoxetine decrease the 
level of pro-inflammatory cytokines in this animal 
model, so the antidepressant effect is achieved 
through an anti-inflammatory effect [24]. 
Curcumin is diarylheptanoid and polyphenol 
component of Curcuma longa which has therapeutic 
and nutritive characteristics. Namely, it is shown that 
curcumin stimulates BDNF and inhibits COX-2 on 
animal (rat) models exposed to chronic distress, so in 
that terms has neuroprotective, possible 
antidepressant effects, as well as the effect on 
neuroplasticity [25]. 
 
 
Immunomodulating effect of 
antidepressants 
 
Biochemical effect of antidepressants has 
been used because of their clinical benefits in certain 
medical disciplines, especially gastroenterology, 
neurology, and for some non-specific disease 
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symptoms. Anti-inflammatory effect of antidepressants 
may be the reason for the wide indications of their use 
[22]. There is certain evidence that antidepressants 
may have immunomodulation performances in animal 
models of depression.  
For example, SSRI Excitaloprame and 
Paroxetine are the agents which decrease pro-
inflammatory markers (TNF, IL-1, IL-6 and PGE-2), 
besides the reduction of depressive symptoms. On 
the other hand, in certain animal models, it has been 
shown that Citalopram increases the level of central 
pro-inflammatory cytokines, like TNF and INF-γ. 
These may be explained by the fact that immune cells 
have neurotransmitter receptors, so antidepressants 
affect these receptors and regulate the immune 
activity. T lymphocytes have 5-hydroxytryptamine (5-
HT) receptors (5-HT1A and 5-HT2A / 2C) on their 
surface. Macrophages express 5-HT system of 
reuptake that is similar to the one of serotonin’s 
reuptake of thrombocytes. Also, antidepressants 
regulate cytokine-induced GR of resistance, by which 
they normalise HPA axis function in depression. They 
inhibit nitrogen-oxide and PGE2 production which is 
increased by cytokine effects and inhibit IDO activity 
as well. They affect macrophages and lymphocytes 
directly, inducing them to produce anti-inflammatory 
cytokines [7], [26]. Also, it was shown that SSRIs 
(Citalopram) performed down-regulation of CD4 
receptor expression, as well as chemokines receptors 
(CCR5, CXR4), in patients infected with human 
immunodeficiency virus (HIV), and that is the manner 
of inhibition of the virus’ entrance in cells and its 
replication. So, it could be told that SSRIs may have 
an adjuvant medication role in immune restitution of 
patients infected with HIV and suffering or not of 
depression [27].  
There are some indications that SSRIs 
stimulate B lymphocytes proliferation in depressive 
patients, so they affect innate immunity. The studies 
investigating the effect of serotonin and noradrenaline 
reuptake inhibitors (SNIRIs) on the immune system, 
both innate and acquired, are scarce. It seems they 
have anti-inflammatory effects, and that may be dose-
dependent. The effects on the immune system 
depend on if patients are early responders, or don’t 
respond to the therapy with SNRIs. It was found that 
they affected certain lymphocytic gene expression, so 
they influence migration, remodelling of cytoskeleton, 
and activation of lymphocytes. There is a small 
number of studies which estimate Venlafaxine and 
Duloxetine influence on inflammation markers. The 
fact is that they influence the levels of Th1 and Th2 
type of cytokines [28]. The theory is that SSRIs target 
Th2 shift during the inflammation, while SNRIs affect 
Th1 shift [22]. Certain researches show more potent 
effects of SSRIs compared to SNRIs. When it is about 
tricyclic antidepressants, there are also a few studies 
investigating their influence on innate and acquired 
immunity, but it is generally accepted that they have 
anti-inflammatory effects, especially by decreasing the 
efficacy of acquired immunity, that is T lymphocytes. 
The small number of studies is about the influence of 
antidepressants on chemokines and represents the 
field that is necessary to investigate further. Until now, 
there has been only one study investigating the 
effects of antidepressants on cytokines in 
cerebrospinal fluid (CSF). It is necessary to include 
more recent antidepressants in further studies, like 
Agomelatine, serotonin and melatonin active agent, 
because it is believed that it has anti-inflammatory 
effects [28]. Few studies are investigating the 
immunomodulation effect of SSRIs, SNRIs and 
monoamine oxidase inhibitors (MAOIs) [29]. It is 
suggested that decreased level of cytokines after 
antidepressant treatment may be connected to the 
increase of T regulatory cells number. Also, the 
immunomodulation effect of electroconvulsive therapy 
(ECT) has been shown in certain studies [10]. 
 
 
Conclusion 
 
The treatment of psychiatric disorders is high 
economic burden nowadays, even though the 
investments in the researches on alterations in 
molecular brain nets represent the platform for new 
therapeutic strategies, which is one of the greatest 
pharmacological and research challenges in XXI 
century. 
So, what can be concluded until now with 
great caution, is that anti-inflammatory therapy can 
potentially be adjuvant treatment together with 
antidepressants, on the one hand, while 
antidepressants on the other, especially those of new 
generation, show inhibitory effects on immune 
processes. Finally, the interaction between 
neurotransmitters and innate and acquired immunity 
should be thoroughly investigated. At this moment, it 
is very hard to bring out definite conclusions, because 
there are still not enough evidence and researches 
which could confirm the clear and undoubted role of 
immune mechanisms in the pathogenesis of 
depression, and consequently the influence of anti-
inflammatory drugs on its therapy. Further studies 
should define methods which would single out the 
components of the immune system in different 
neuroanatomic regions. More specifically, their role is 
to complete the palette of biomarkers which would 
enable a personalized approach to every single 
patient and deal with dilemmas referring to resistance 
to medications. Neurobiological and neuroimmunology 
studies done so far only partly explained complex 
pathophysiology of depressive disorder, so numerous 
proposed therapeutic interventions are still in 
conceptual and preclinical stages. 
It is very important to emphasise that those 
immunomodulation drugs for which there are 
significant indications of clinical benefits should pass 
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the phase of more thorough testing on tolerability, 
efficacy, and safety, so after that, their implementation 
into therapeutic protocols for depression treatment 
can be considered. 
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